{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:32:57Z","timestamp":1789018377839,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007467","name":"Keio University School of Medicine Graduate School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007467","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jiac.2021.04.018","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T07:51:17Z","timestamp":1620114677000},"page":"1311-1318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Multiple comorbidities increase the risk of death from invasive pneumococcal disease under the age of 65 years"],"prefix":"10.1016","volume":"27","author":[{"given":"Shigeo","family":"Hanada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Morozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seitaro","family":"Fujishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8934-2477","authenticated-orcid":false,"given":"Kimiko","family":"Ubukata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2021.04.018_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060273","article-title":"Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques","volume":"8","author":"Said","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jiac.2021.04.018_bib2","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1017\/S0950268810000919","article-title":"Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies","volume":"138","author":"Wong","year":"2010","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jiac.2021.04.018_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/431521","article-title":"The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults","volume":"192","author":"Kyaw","year":"2005","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib4","first-page":"17","article-title":"The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England","volume":"65","author":"van Hoek","year":"2012","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.jiac.2021.04.018_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/cid\/civ803","article-title":"Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs","volume":"62","author":"Shigayeva","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: updated recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jiac.2021.04.018_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/jgid.jgid_88_17","article-title":"A\u00a0simple approach to pneumococcal vaccination in adults","volume":"10","author":"Green","year":"2018","journal-title":"J\u00a0Global Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.vaccine.2016.02.024","article-title":"The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis","volume":"34","author":"Kraicer-Melamed","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jiac.2021.04.018_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1473-3099(17)30049-X","article-title":"Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study","volume":"17","author":"Suzuki","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169368","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis","volume":"12","author":"Falkenhorst","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.jiac.2021.04.018_bib11","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2021.04.018_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jiac.2018.01.004","article-title":"Impact of the National Routine Vaccination Program on 23-valent pneumococcal polysaccharide vaccine vaccination rates in elderly persons in Japan","volume":"24","author":"Naito","year":"2018","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2021.04.018_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1086\/377534","article-title":"An international prospective study of pneumococcal bacteremia: correlation with in\u00a0vitro resistance, antibiotics administered, and clinical outcome","volume":"37","author":"Yu","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1086\/518538","article-title":"Association of serotypes of streptococcus pneumoniae with disease severity and outcome in adults: an international study","volume":"45","author":"Alanee","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/thoraxjnl-2012-203106","article-title":"Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia","volume":"68","author":"Naucler","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jiac.2021.04.018_bib16","article-title":"Host factors and biomarkers associated with poor outcomes in adults with invasive pneumococcal disease","volume":"11","author":"Hanada","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jiac.2021.04.018_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2017.06.039","article-title":"Effect of age on the manifestations and outcomes of invasive pneumococcal disease in adults","volume":"131","author":"Marrie","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.jiac.2021.04.018_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa043","article-title":"Characteristics of invasive pneumococcal disease (IPD) caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in England; prospective observational cohort study, 2014-18","volume":"71","author":"Amin-Chowdhury","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib19","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3201\/eid2411.180326","article-title":"Effects of pneumococcal conjugate vaccine on genotypic penicillin resistance and serotype changes, Japan, 2010-2017","volume":"24","author":"Ubukata","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib20","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1016\/j.vaccine.2016.07.003","article-title":"Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults","volume":"34","author":"Baxter","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jiac.2021.04.018_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(05)70288-X","article-title":"Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series","volume":"5","author":"Weisfelt","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jiac.2021.04.018_bib22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1473-3099(15)00430-2","article-title":"Community-acquired bacterial meningitis in adults in The Netherlands, 2006-14: a prospective cohort study","volume":"16","author":"Bijlsma","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib23","doi-asserted-by":"crossref","DOI":"10.3201\/eid2111.142029","article-title":"Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010-2013","volume":"21","author":"Ubukata","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2807\/1560-7917.ES2014.19.31.20869","article-title":"Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009-2011","volume":"19","author":"Verhaegen","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jiac.2021.04.018_bib25","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/21645515.2019.1690332","article-title":"A\u00a0Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older","volume":"16","author":"Kawakami","year":"2020","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jiac.2021.04.018_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018553","article-title":"Risk of pneumococcal diseases in adults with underlying medical conditions: a retrospective, cohort study using two Japanese healthcare databases","volume":"8","author":"Imai","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jiac.2021.04.018_bib27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/thoraxjnl-2019-213725","article-title":"Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18","volume":"75","author":"Pick","year":"2020","journal-title":"Thorax"},{"key":"10.1016\/j.jiac.2021.04.018_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220453","article-title":"Limited indirect effects of an infant pneumococcal vaccination program in an aging population","volume":"14","author":"van der Linden","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.jiac.2021.04.018_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00478-17","article-title":"Genome evolution to penicillin resistance in serotype 3 Streptococcus pneumoniae by capsular switching","volume":"61","author":"Chiba","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2021.04.018_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jiac.2020.09.014","article-title":"Molecular epidemiological characterization in mucoid-type Streptococcus pneumoniae isolates obtained from invasive pneumococcal disease patients in Japan","volume":"27","author":"Ubukata","year":"2021","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2021.04.018_bib31","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/cid\/ciy920","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies","volume":"68","author":"Sings","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib32","first-page":"2135","article-title":"Factors associated with severe nonmeningitis invasive pneumococcal disease in adults in France","volume":"68","author":"Danis","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib33","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/cid\/ciy312","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design","volume":"67","author":"McLaughlin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2021.04.018_bib34","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age","author":"Hurley","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21001252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21001252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:01:57Z","timestamp":1761159717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X21001252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1341321X21001252"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2021.04.018","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple comorbidities increase the risk of death from invasive pneumococcal disease under the age of 65 years","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2021.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}